- Home
- CATX vs BIOA Comparison
CATX vs BIOA Comparison
Compare CATX & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | BIOA |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.5M | 255.6M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CATX | BIOA |
|---|---|---|
| Price | $1.23 | $5.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 10 |
| Target Price | $11.43 | ★ $32.56 |
| AVG Volume (30 Days) | ★ 2.5M | 818.8K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.20 | $97.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $4.81 |
| 52 Week High | $6.16 | $25.96 |
Technical Indicators
Market Signals| Indicator | CATX | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 21.38 | 43.10 |
| Support Level | N/A | $4.81 |
| Resistance Level | $3.67 | $8.53 |
| Average True Range (ATR) | 0.23 | 0.39 |
| MACD | -0.12 | 0.17 |
| Stochastic Oscillator | 7.37 | 63.25 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.